Hereditary nonpolyposis colorectal cancer secondary prevention: Difference between revisions
No edit summary |
|||
Line 10: | Line 10: | ||
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include:<ref name="hnpcc">Kladny J, Lubinski J. Lynch syndrome (HNPCC). Hered Cancer Clin Pract. 2008;6(2):99-102.</ref> | Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include:<ref name="hnpcc">Kladny J, Lubinski J. Lynch syndrome (HNPCC). Hered Cancer Clin Pract. 2008;6(2):99-102.</ref> | ||
* Colonoscopy 25-35 years | * Colonoscopy between 25-35 years, every 2 years. | ||
* Pelvic exam, transvaginal ultrasound and CA-125 25-35 years | * Pelvic exam, transvaginal ultrasound and CA-125 between 25-35 years, every year. | ||
* Endometrial biopsy | * Endometrial biopsy, in relation to clinical symptoms. | ||
* Urine cytology - Families who have someone diagnosed with transitional cell carcinoma of the ureter or renal pelvis 25-35 years | * Urine cytology - Families who have someone diagnosed with transitional cell carcinoma of the ureter or renal pelvis, between 25-35 years every year. | ||
==References== | ==References== |
Revision as of 16:01, 7 December 2015
Hereditary Nonpolyposis Colorectal Cancer Microchapters |
Differentiating Hereditary Nonpolyposis Colorectal Cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hereditary nonpolyposis colorectal cancer secondary prevention On the Web |
American Roentgen Ray Society Images of Hereditary nonpolyposis colorectal cancer secondary prevention |
FDA on Hereditary nonpolyposis colorectal cancer secondary prevention |
CDC on Hereditary nonpolyposis colorectal cancer secondary prevention |
Hereditary nonpolyposis colorectal cancer secondary prevention in the news |
Blogs on Hereditary nonpolyposis colorectal cancer secondary prevention |
Directions to Hospitals Treating Hereditary nonpolyposis colorectal cancer |
Risk calculators and risk factors for Hereditary nonpolyposis colorectal cancer secondary prevention |
Overview
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include genetic testing, colonoscopy, urine cytology, pelvic exam and endometrial biopsy.[1]
Secondary prevention
Recent studies demonstrate a reduced incidence in Lynch Syndrome patients who were exposed to at least four years of high-dose aspirin, with a satisfactory risk profile. These results have been widely covered in the media; future studies will look at modifying (lowering) the dose (to reduce risk associated with the high dosage of ASA).
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include:[1]
- Colonoscopy between 25-35 years, every 2 years.
- Pelvic exam, transvaginal ultrasound and CA-125 between 25-35 years, every year.
- Endometrial biopsy, in relation to clinical symptoms.
- Urine cytology - Families who have someone diagnosed with transitional cell carcinoma of the ureter or renal pelvis, between 25-35 years every year.